Kintor PharmaceuticalKNTPF 26 Receivables Turnover is 9.55 as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Kintor Pharmaceutical ranks better than 81.81% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kintor Pharmaceutical's Revenue for the
six
months ended in Dec. 2025 was $3.79 Mil. Kintor Pharmaceutical's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.40 Mil.
Hence, Kintor Pharmaceutical's Receivables Turnover for the
six
months ended in Dec. 2025 was 9.55.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kintor Pharmaceutical Receivables Turnover Related Terms
Kintor Pharmaceutical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a Receivables Turnover of 9.55 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #153 out of 841 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Kintor Pharmaceutical's Receivables Turnover too high?
Kintor Pharmaceutical's current Receivables Turnover is 9.55. The Biotechnology industry median Receivables Turnover is 5.29. Kintor Pharmaceutical's value of 9.55 is 80.5% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #153 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #153 out of 841 companies for Receivables Turnover. This places Kintor Pharmaceutical in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Kintor Pharmaceutical's value of 9.55 is 80.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Receivables Turnover of 9.55 is 80.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Receivables Turnover is 9.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Receivables Turnover of 9.55. The current Receivables Turnover is 9.55 and 80.5% above the Biotechnology industry median of 5.29. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Receivables Turnover is 9.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score
Get the complete analysis for KNTPF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
